Analytical Epidemiology
It is primarily designed to establish the causes of disease by investigating the association between exposure to a risk factor and the occurrence of disease.
- Objective of this study → Hypothesis testing.
- Analytical epidemiology has 4 types:
- Ecological study
- Cross-sectional study
- Case-control study
- Cohort study
Ecological Study
- Also known as correlational study.
- Type of analytical epidemiological study, which provides the least satisfactory type of evidence on causality.
- It is the least preferable analytical design.
- Units of study → population.
- Done in a small time frame, uses data which is already available.
Cross-Sectional Study
- It is the simplest form of analytical study.
- These studies are surveys that take place over a limited period.
- Based on the single examination of a cross-section of a population ‘at one point of time’.
- Results of the sample are projected to the whole population.
- This study provides prevalence of disease.
- It is a ‘snapshot’ of the population.
- More useful for chronic disease.
- Gives information about the distribution of disease, not its etiology.
- Unit of study → Individual.

Epidemiological Study Types
| Type of Epidemiological Study | Unit of Study |
|---|---|
| 1. Observational studies | |
| a. Descriptive studies (Hypothesis formulation) | |
| b. Analytical studies (Hypothesis testing) | |
| i. Cohort study | Individual |
| ii. Case-control study | Individual |
| iii. Cross-sectional study | Individual |
| iv. Ecological study | Population |
| 2. Experimental studies (Hypothesis confirmation) | |
| a. Randomized controlled trial | Patients |
| b. Field trial | Healthy people |
| c. Community trial | Community |
| d. Clinical trial | Patients |

Case Control Study
Other Names:
- Case reference study
- Retrospective study
- TROHOC study
- Backward looking study
- Effect to cause study
- Outcome to exposure study
- Disease to risk factor study
→ Unit of study → Individual.
→ This study is not expensive.
Advantages:
- Useful to study rare disease.
- Easy to carry out.
- Rapid and inexpensive.
- No loss to follow-up/ Attrition.
- Requires few subjects.
→ This study gives information about many risk factors for a single disease.
Disadvantages:
- Recall bias and selection bias are present.
- Cannot measure incidence.
→ Strength of association in case control study → odds ratio (cross product ratio).
Cohort Studies
Other Names:
- Prospective study
- Forward-looking study
- Causes to effect study
- Exposure to outcome study
- Risk factor to disease study
- Incidence study
- Follow-up study
→ This study ends with the disease.
→ It determines a single risk factor affecting many diseases.
→ Units of study → Individual.
Types of Cohort Study:
a) Prospective Cohort Study
- Known as current cohort study or concurrent cohort study.
- Only exposure has occurred when the study has begun.
Examples:
- Framingham heart study.
- Doll and Hill’s prospective study on smoking and lung cancer.
b) Retrospective Cohort Study
- Known as historical cohort study or non-concurrent cohort study.
- It has combined advantages of both cohort study and case-control study.
- Both exposure as well as outcome have occurred when the study has begun.
Examples:
- Effects of fetal monitoring on neonatal deaths.
- PVC exposure and angiosarcoma of the liver.
c) Combined Prospective-Retrospective Cohort Study
- Known as ‘mixed cohort study’.
Strength of Association in Cohort Study:
→ It is evaluated by:
- Relative Risk (RR)
- Attributable Risk (AR)
- Population Attributable Risk (PAR)

Comparison of Study Designs
| Characteristic | Cross-sectional studies | Case-control studies | Cohort studies |
|---|---|---|---|
| Time | One time point | Retrospective | Prospective |
| Other names | Prevalence study | Case reference study |
|
| Incidence | No | No | Allows the study of incidence |
| Prevalence | Allows the study of prevalence | No | No |
| Causality | No | Yes | Yes |
| Role of disease | Measures disease | Begin with disease | End with disease |
| Assesses | Association of risk factor and disease | Many risk factors for a single disease | Single risk factor affecting many diseases |
| Data analysis | Chi-square to assess association | Odds ratio to estimate risk | Provides direct estimate of relative risk (COMEDK – 2013) |
| Advantages |
|
|
|
| Disadvantages |
|
|
|
Epidemiological Studies Summary
| Ecological Study | Cross Sectional Study | Case Control Study | Cohort Study |
|---|---|---|---|
|
|
|
|

Experimental Epidemiology
Randomized Controlled Trials (RCTs)
→ RCT is of two types:
Concurrent Parallel Design:
→ Comparisons are made between 2 groups:
- Experimental group: Is exposed to specific medication or intervention.
- Reference group: Is not exposed to specific medication or intervention.
Crossover Design:
→ Comparisons are made between 2 groups:
- Experimental group: Is exposed to specific medication or intervention.
- Reference group: Is not exposed to specific medication or intervention.
→ Then the groups are crossed-over (Exposed group now becomes non-exposed and vice-versa).
→ Crossover design RCT helps removing ethical concerns.
Intention to Treat Trial:
→ Implies that the results of an RCT are unaffected by attrition (Loss to follow-up) or changeover of study subjects from one group to another.
Randomization in RCT:
→ It is a statistical procedure, by which participants are allocated into either of two groups:
- Experimental group: In which intervention is given.
- Reference group: In which intervention is not given.
→ Randomization is best done by ‘Random number tables’.
Pre-Clinical & Clinical Trials
| Phase | Unit of Study | Purpose |
|---|---|---|
| PRECLINICAL PHASE | ||
| Lab experiments | Animals | Pretesting |
| CLINICAL PHASES | ||
| Phase 0 | Healthy human volunteers | Micro-dosing |
| Phase I | Healthy human volunteers | Safety and non-toxicity profile |
| Phase II | Patients | Effectiveness |
| Phase III | Patients | Comparison with existing drug |
| Phase IV | Patients | Long-term side effects |
- Phase III is an RCT: Comparison of a new drug with an existing old drug.
- New drug is launched in market after: Phase III.
- Longest phase of a trial: Phase IV.
- Post-marketing surveillance: Phase IV.
- Maximum tolerated dose (MTD) of a drug: Phase I.

Leave a Reply